India's top drug maker, Sun Pharmaceutical Industries has reported results for the first quarter ended June 30, 2012.
The company's net profit for the quarter, on standalone basis, has declined by 30.85% at Rs 292.63 crore as compared to Rs 423.20 crore for the quarter ended June 30, 2011. The company's total income has increased marginally by 4.45% to Rs 984.65 crore for the quarter under review from Rs 942.73 crore for the corresponding quarter of the previous year.
On consolidated basis, Group's Q1FY13 net profit after taxes, minority interest surged by 58.79% at Rs 795.55 crore as compared to Rs 501.00 crore for the Q1FY12. Group's total income has increased by 52.12% to Rs 2656.25 crore for the quarter from Rs 1746.20 crore for the similar quarter of previous year.
Further, the company's board of directors further declared the interim dividend of Rs 4.25 per share of Re 1 each on equity shares of the company for the year ended March 31, 2012 in lieu of the earlier proposed dividend of Rs 4.25 per share of Re 1 each on equity shares of the company for the year ended March 31, 2012.
Sun Pharma is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.